Modified Ketamine Derivatives for Long-Acting Low-Addiction Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ketamine derivatives, such as (2R,6R;2S,6S)-hydroxynorketamine (HNK), have a short efficacy duration of less than one week and pose a risk of addiction, limiting their effectiveness in long-term treatment of depression and other conditions.
Innovation Solution
A modified ketamine derivative, represented by Formula III, with specific substituents and configurations, is developed to extend efficacy beyond one week and reduce addiction, with compounds like Formula IV and Formula V being preferred.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional ketamine derivatives like HNK are used for treatment, then antidepressant and analgesic effects are achieved, but the efficacy duration is short (less than one week) and addiction risk is high
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of ketamine derivatives through varying substituents (R1-R6 groups) at different positions on the molecular framework. This structural parameter optimization extends the efficacy duration from less than one week to more than one week while simultaneously reducing addiction risk by 2-20 times compared to traditional HNK compounds
Solution Approach 2:
The patent creates composite molecular structures by combining the core ketamine derivative framework with various functional substituent groups (hydroxyl, amino, alkyl, aryl, heterocyclic groups). These composite structures achieve synergistic effects where the base structure provides the core pharmacological activity while the substituents modulate duration and addiction properties
2Speed
If ketamine is used for anesthesia and analgesia, then strong analgesic effect and rapid induction are achieved, but psychiatric side effects and cognitive impairment occur
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at particular positions on the ketamine derivative molecule. These localized structural modifications target specific receptor interactions to enhance analgesic and anesthetic effects while minimizing activation of pathways that cause psychiatric side effects and cognitive impairment
Solution Approach 2:
Through systematic variation of substituent parameters (type, position, and configuration), the patent optimizes the balance between rapid induction/strong analgesia and reduction of harmful psychiatric effects, achieving a more favorable side effect profile while maintaining clinical efficacy
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The present application relates to a compound having the effects of being an antidepressant, anesthetizing, alleviating pain, improving cognitive functions, protecting lungs, preventing or treating amyotrophic lateral sclerosis or preventing or treating complex regional pain syndrome. Compared with existing known HNK compounds, the compound provided in the present application has a longer drug efficacy period. Moreover the compound provided in the present application basically does not produce addiction.